Xencor Inc. (NASDAQ:XNCR) rose 2.6% during trading on Friday . The company traded as high as $21.76 and last traded at $21.41, with a volume of 87,188 shares changing hands. The stock had previously closed at $20.86.

XNCR has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday, July 5th. Canaccord Genuity restated a “buy” rating on shares of Xencor in a report on Tuesday, May 3rd. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Xencor in a report on Monday, May 2nd. Leerink Swann restated an “outperform” rating and issued a $18.00 price objective on shares of Xencor in a report on Wednesday, June 29th. Finally, Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a report on Tuesday, June 28th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Xencor currently has an average rating of “Buy” and a consensus target price of $22.33.

The company has a market capitalization of $879.17 million and a price-to-earnings ratio of 22.82. The company has a 50-day moving average of $20.01 and a 200 day moving average of $14.93.

Xencor (NASDAQ:XNCR) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.31. The business earned $66 million during the quarter, compared to analysts’ expectations of $7.43 million. Equities research analysts predict that Xencor Inc. will post $0.72 earnings per share for the current fiscal year.

In other Xencor news, major shareholder John S. Stafford III sold 10,000 shares of Xencor stock in a transaction on Monday, August 15th. The shares were sold at an average price of $23.06, for a total transaction of $230,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder John S. Stafford III sold 96,828 shares of Xencor stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $21.73, for a total transaction of $2,104,072.44. The disclosure for this sale can be found here.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.